The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 895-902

  Li, Jiang ^a   Liu, Hui ^a   Li, Linfang ^a   Wu, Hongping ^a   Wang, Chunhong ^a   Yan, Zi ^a   Wang, Ying ^a   Su, Changqing ^a   Jin, Huajun ^a   Zhou, Fuping ^a   Wu, Mengchao ^a   Qian, Qijun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Adoptive immunotherapy; Gene therapy; Hepatoma; RANTES

Indexed keywords

MEMBRANE COFACTOR PROTEIN; ONCOLYTIC ADENOVIRUS; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL HYPOXIA; CHEMOTAXIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSION GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CCL5; CHEMOTAXIS; COMBINED MODALITY THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN; VIRUS REPLICATION;

EID: 84872795043     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2217     Document Type: Article

References (47)

1. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE and Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.
2. Dudley ME, Wunderlich JR, Shelton TE, Even J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342, 2003. (Pubitemid 36858717)
3. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo N P, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005. (Pubitemid 46218728)
4. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA and Restifo NP: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33: 1-7, 2010.
5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE and Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immuno-therapy Clin Cancer Res 17: 4550-4557, 2011.
6. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA and Avital I: Liver resection for metastatic melanoma with postoperative tumor-infltrating lymphocyte therapy. Ann Surg Oncol 17: 163-170, 2010.
7. Rosenberg SA and Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240, 2009.
8. Pittet MJ and Mempel TR: Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol Rev 221: 107-129, 2008. (Pubitemid 351230111)
9. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, Broxmeyer HE and Cornetta K: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164: 4025-4031, 2000. (Pubitemid 30215056)
10. Hromas R, Cripe L, Hangoc G, Cooper S and Broxmeyer HE: The exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors. Blood 95: 1506-1508, 2000. (Pubitemid 30099869)
11. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK and Dubinett SM: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164: 4558-4563, 2000. (Pubitemid 30238052)
12. Kudo T, Lu H, Wu JY, Graham DY, Casola A and Yamaoka Y: Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun 73: 7602-7612, 2005. (Pubitemid 41587667)
13. Lebovic DI, Chao VA and Taylor RN: Peritoneal macrophages induce RANTES (regulated on activation, normal T cell expressed and secreted) chemokine gene transcription in endometrial stromal cells. J Clin Endocrinol Metab 89: 1397-1401, 2004. (Pubitemid 38368443)
14. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE and Mach F: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94: 253-261, 2004. (Pubitemid 38197459)
15. Rojas-Ramos E, Avalos AF, Pérez-Fernandez L, Cuevas-Schacht F, Valencia-Maqueda E and Terán LM: Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4 and eotaxins-1 and -2 in childhood asthma. Eur Respir J 22: 310-316, 2003. (Pubitemid 36987003)
16. Chen CJ, Chen JH, Chen SY, Liao SL and Raung SL: Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol 78: 12107-12119, 2004.
17. Oltmanns U, Issa R, Sukkar MB, John M and Chung KF: Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 139: 1228-1234, 2003. (Pubitemid 36920687)
18. Teichmann JV, Ludwig WD and Thiel E: Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk Res 16: 287-298, 1992.
19. Pawelec G: MHC-unrestricted immune surveillance of leukemia. Cancer Biother 9: 265-288, 1994.
20. Dokhelar MC, Wiels J, Lipinski M, Tetaud C, Devergie A, Gluckman E and Tursz T: Natural killer cell activity in human bone marrow recipients: early reappearance of peripheral natural killer activity in graft-versus-host disease. Transplantation 31: 61-65, 1981. (Pubitemid 11155054)
21. Cerwenka A and Lanier LL: Natural killer cells, viruses and cancer. Nat Rev Immunol 1: 41-49, 2001. (Pubitemid 33741974)
22. Lanier LL: NK cell recognition. Annu Rev Immunol 23: 225-274, 2005. (Pubitemid 40563170)
23. Drexler HG and Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 14: 777-782, 2000. (Pubitemid 30235051)
24. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J and O'Reilly RJ: Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4: 2859-2868, 1998. (Pubitemid 28523516)
25. Gong JH, Maki G and Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. (Pubitemid 24133034)
26. Reid GS, Bharya S, Klingemann HG and Schultz KR: Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clin Exp Immunol 129: 265-271, 2002.
27. Tam YK, Miyagawa B, Ho VC and Klingemann HG: Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8: 281-290, 1999. (Pubitemid 29310062)
28. Tonn T, Becker S, Esser R, Schwabe D and Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10: 535-544, 2001. (Pubitemid 32756192)
29. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL and Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997. (Pubitemid 27114163)
30. Tomko RP, Xu R and Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356, 1997. (Pubitemid 27157315)
31. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT and Douglas JT: The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38: 1917-1926, 2002. (Pubitemid 35247478)
32. Matsumoto K, Shariat SF, Ayala GE, Rauen KA and Lerner SP: Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 66: 441-446, 2005. (Pubitemid 41138121)
33. Yamamoto H, Itoh F, Sakamoto H, Nakajima Y, Une Y, Hinoda Y and Imai K: Association of reduced cell adhesion regulator messenger RNA expression with tumor progression in human hepatocellular carcinoma. Int J Cancer 74: 251-254, 1997. (Pubitemid 27321791)
34. Gaggar A, Shayakhmetov DM and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412, 2003. (Pubitemid 37466191)
35. Hara T, Kojima A, Fukuda H, Masaoka T, Fukumori Y, Matsumoto M and Seya T: Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol 82: 368-373, 1992.
36. Kinugasa N, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Ishizaki M, Toshikuni N, Yoshida K, Uematsu S and Tsuji T: Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer 80: 1820-1825, 1999. (Pubitemid 29389639)
37. Murray K P, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG and Kaul A: Expression of complement regulatory proteins-CD 35, CD 46, CD 55 and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 76: 176-182, 2000. (Pubitemid 30067192)
38. Thorsteinsson L, O'Dowd GM, Harrington PM and Johnson PM: The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 106: 869-878, 1998. (Pubitemid 28468843)
39. Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy, Cancer Lett 254: 178-216, 2007. (Pubitemid 47126688)
40. Liu X, Qian Q, Xu P, Wolf F, Zhang J, Zhang D, Li C and Huang Q: A novel conditionally replicating 'armed' adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling. Hum Gene Ther 22: 427-437, 2011.
41. Xie M, Niu JH, Chang Y, Qian QJ, Wu H P, Li LF, Zhang Y, Li JL, Huang XJ and Ruan GR: A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 14: 1086-1094, 2009.
42. Harada H, Hiraoka M and Kizaka-Kondoh S: Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018, 2002. (Pubitemid 34408445)
43. Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139-168, 1994. (Pubitemid 24220002)
44. Kung AL, Wang S, Klco JM, Kaelin WG and Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000. (Pubitemid 32001016)
45. Helmlinger G, Yuan F, Dellian M and Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182, 1997. (Pubitemid 27064702)
46. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
47. Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M and Qian Q: Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dualregulated oncolytic adenovirus. Clin Cancer Res 12: 6523-6531, 2006. (Pubitemid 44799727)